About MultiVir

MultiVir is a clinical stage, immune oncology company pioneering a new field of cancer therapeutics termed Tumor Suppressor Immune Gene Therapy employing multiple viral delivery platforms. MultiVir’s oncology products deliver tumor suppressor and immunotherapeutic genes. The company’s broad technology platforms target cancers’ most fundamental and common molecular defects.

MultiVir’s product candidates have unique therapeutic activities with multiple mechanisms of action. MultiVir’s tumor suppressor gene therapies have the ability to inhibit tumor growth, kill cancerous cells, enhance anti-tumor immunity, decrease tumor blood supply, and the potential to sensitize tumors to conventional immunotherapy, chemotherapy and radiation treatments. In clinical trials to date, the products have been generally well-tolerated, with only transient adverse effects.